drugset / Trial / NCT06987383
Vibegron for ENergy Thinking and Resilience in Aging
Phase 3
Not yet recruiting
40 enrolled
Wake Forest University Health Sciences
National Institute on Aging (NIA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Timeline
- Start
- 2026-08
- Primary completion
- 2028-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vibegron | Unknown | 75 mg | Oral |